ESSEX, Conn.--(BUSINESS WIRE)--Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback